Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Boehringer Ingelheim
Dow
AstraZeneca
McKinsey

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,195,375

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,195,375
Title:Airflow adaptor for a breath-actuated dry powder inhaler
Abstract: An airflow adaptor for a breath-actuated dry powder inhaler. The airflow adaptor includes a conduit having a proximal end and a distal end, wherein the proximal end allows fluid communication from a deagglomerator outlet port to the distal end of the conduit, and wherein the airflow adaptor further includes provisions for allowing air to flow from a proximal end of the adaptor to a distal end of the adaptor independently of the airflow in the conduit when a breath induced low pressure is applied to the distal end of the airflow adaptor.
Inventor(s): Blair; Julian Alexander (Stradbally, IE), Buck; Daniel (Waterford, IE), Hazenberg; Jan Geert (Kilkenny, IE), Zeng; Xian-Ming (London, GB)
Assignee: NORTON HEALTHCARE LIMITED (West Yorkshire, GB)
Application Number:15/270,160
Patent Claims: 1. An airflow adaptor for a breath-actuated dry powder inhaler, the airflow adaptor comprising: a first conduit having a proximal end and a distal end, wherein the proximal end allows fluid communication from a deagglomerator outlet port to the distal end of the first conduit, and wherein the airflow adaptor further comprises at least one second conduit configured to allow air to flow from a proximal end of the adaptor to a distal end of the adaptor independently of the airflow in the first conduit when a breath induced low pressure is applied to the distal end of the airflow adaptor, and wherein the distal end of the first conduit is located at the distal end of the airflow adaptor and comprises a first aperture in a first circumferential flange, and the second conduit is in the form of at least one second aperture in the first circumferential flange.

2. An airflow adaptor according to claim 1 wherein a ratio of the sum of the cross-sectional areas of the at least one second conduit to the cross-sectional area of the first conduit is such that when a breath induced low pressure is applied to the distal end of the airflow adaptor at least 5% of the resulting airflow is through the at least one second conduit.

3. An airflow adaptor according to claim 1 wherein the first circumferential flange comprises at least two second apertures.

4. An airflow adaptor according to claim 1 wherein the airflow adaptor comprises a second circumferential flange at the proximal end of the airflow adaptor, wherein the first conduit comprises a first aperture, the second circumferential flange further comprising at least one second aperture which forms part of the second conduit.

5. An airflow adaptor according to claim 4 wherein the ratio of the sum of the cross-sectional areas of the second apertures in the second circumferential flange to the cross-sectional area of the first conduit is such that when a pressure breath induced low pressure is applied to the distal end of the airflow adaptor at least 5% of the resulting airflow is through the second apertures.

6. A deagglomerator for a breath-actuated dry powder inhaler, the deagglomerator comprising an airflow adaptor according to claim 1.

7. The deagglomerator according to claim 6, the deagglomerator comprising: an inner wall defining a swirl chamber extending along an axis from a first end to a second end; a dry powder supply port in the first end of the swirl chamber for providing fluid communication between a dry powder delivery passageway of an inhaler and the first end of the swirl chamber; at least one inlet port in the inner wall of the swirl chamber adjacent to the first end of the swirl chamber providing fluid communication between a region exterior to the deagglomerator and the first end of the swirl chamber; an outlet port providing fluid communication between the second end of the swirl chamber and the airflow adaptor; whereby a breath induced low pressure at the distal end of the airflow adaptor causes air to flow into the swirl chamber through the dry powder supply port and the inlet port.

8. A deagglomerator for a breath-actuated dry powder inhaler, the deagglomerator comprising: an inner wall defining a swirl chamber extending along an axis from a first end to a second end; a dry powder supply port in the first end of the swirl chamber for providing fluid communication between a dry powder delivery passageway of an inhaler and the first end of the swirl chamber; at least one inlet port in the inner wall of the swirl chamber adjacent to the first end of the swirl chamber providing fluid communication between a region exterior to the deagglomerator and the first end of the swirl chamber; an outlet port providing fluid communication between the second end and an airflow adaptor, the airflow adaptor providing fluid communication between the outlet port and a region exterior to the deagglomerator via a first conduit, wherein the distal end of the first conduit is located at the distal end of the airflow adaptor and comprises a first aperture in a first circumferential flange; and wherein the airflow adaptor comprises at least one second conduit that by-passes the swirl chamber and directs air to flow from a proximal end of the airflow adaptor to a distal end of the airflow adaptor independently of the first conduit when a breath-induced low pressure is applied to the distal end of the airflow adaptor, wherein the second conduit comprises a second aperture in the first circumferential flange.

9. A deagglomerator according to claim 8 wherein the breath induced low pressure at the distal end of the airflow adaptor causes air to flow into the swirl chamber through the dry powder supply port and the inlet port.

10. A deagglomerator according to claim 8 wherein a ratio of the sum of the cross-sectional area of the at least one second conduit to the cross-sectional area of the outlet port is such that that when a pressure breath induced low pressure is applied to the distal end of the airflow adaptor at least 5% of the resulting airflow is directed through the at least one second conduit.

11. A deagglomerator according to claim 8 wherein the at least one second conduit is in the form of at least one second aperture in the first circumferential flange.

12. A breath-actuated dry powder inhaler comprising an airflow adaptor according to claim 1.

13. The breath-actuated dry powder inhaler according to claim 12 wherein the inhaler comprises a dry powder medicament.

14. A breath-actuated dry powder inhaler comprising a deagglomerator according to claim 8.

15. The breath-actuated dry powder inhaler according to claim 14 wherein the inhaler comprises a dry powder medicament.

16. The breath-actuated dry powder inhaler according to claim 15 wherein the dry powder medicament comprises an active ingredient selected from the group consisting of an anti-inflammatory agent, an anti-cholinergic agent, a .beta.2-adrenoreceptor agonist, an anti-infective agent, an antihistamine and combinations thereof.

17. The breath-actuated dry powder inhaler according to claim 16 wherein the active ingredient comprises fluticasone propionate.

18. The breath-actuated dry powder inhaler according to claim 17 wherein the active ingredient comprises a combination of fluticasone propionate and salmeterol xinafoate.

19. The breath-actuated dry powder inhaler according to claim 13 wherein the dry powder medicament comprises an active ingredient selected from the group consisting of an anti-inflammatory agent, an anti-cholinergic agent, a .beta.2-adrenoreceptor agonist, an anti-infective agent, an antihistamine and combinations thereof.

20. The breath-actuated dry powder inhaler according to claim 19 wherein the active ingredient comprises fluticasone propionate.

21. The breath-actuated dry powder inhaler according to claim 20 wherein the active ingredient comprises a combination of fluticasone propionate and salmeterol xinafoate.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Mallinckrodt
Merck
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.